| dc.creator | Meneses Calderón, José;#0000-0001-6848-8434 | |
| dc.creator | Mendieta Zerón, Hugo; 45175 | |
| dc.creator | Padmanabhan, Srivatsan;#0000-0003-2958-1390 | |
| dc.creator | Meneses Calderón, José | |
| dc.creator | Mendieta Zerón, Hugo | |
| dc.creator | Padmanabhan, Srivatsan | |
| dc.date | 2020-08-13T15:52:51Z | |
| dc.date | 2020-08-13T15:52:51Z | |
| dc.date | 2020-06 | |
| dc.date.accessioned | 2022-10-13T00:00:26Z | |
| dc.date.available | 2022-10-13T00:00:26Z | |
| dc.identifier | 1745-6215 | |
| dc.identifier | http://hdl.handle.net/20.500.11799/109079 | |
| dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/4152776 | |
| dc.description | Objectives: To determine the efficacy of Hydroxychloroquine vs. Hydroxychloroquine + Nitazoxanide in reducing the need for invasive mechanical ventilatory support for patients with COVID-19. Hydroxychloroquine is currently being used in multiple trials with varying doses in an attempt to treat COVID-19. Nitazoxanide has powerful antiviral effects and proven efficacy against a range of viruses including SARS and MERS. Dual therapy by combining appropriate doses of these two medications with diverse activities against COVID-19 is expected to be better than monotherapy with hydroxychloroquine. Trial design: This is a single centre, randomized, controlled, single blinded, 2 arm (ratio 1:1) parallel group trial. | |
| dc.language | eng | |
| dc.publisher | Trials | |
| dc.relation | 21 | |
| dc.rights | openAccess | |
| dc.rights | http://creativecommons.org/licenses/by-nc-nd/4.0 | |
| dc.subject | Hydroxychloroquine | |
| dc.subject | Nitazoxanide | |
| dc.subject | COVID-19 | |
| dc.subject | Risk factors | |
| dc.subject | MEDICINA Y CIENCIAS DE LA SALUD | |
| dc.title | Treatment with Hydroxychloroquine vs Hydroxychloroquine + Nitazoxanide in COVID-19 patients with risk factors for poor prognosis: A structured summary of a study protocol for a randomised controlled trial. | |
| dc.type | Artículo | |
| dc.type | article | |
